NCT03953352 2026-04-15
GIRAFE
Institut Claudius Regaud
Phase NA Withdrawn
Clinical Trials
23 trialsNCT05664893 2026-04-15
CALHYS
Centre Antoine Lacassagne
Phase 1/2 Withdrawn
NCT07082270 2026-04-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT02872831 2026-04-13
Beacon BNXâ„¢ Endoscopic Ultrasound (EUS)-Needle vs SharkCoreâ„¢ Needle
Thomas Jefferson University
Phase NA Withdrawn
NCT06767956 2026-04-13
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
Phase 1/2 Withdrawn
NCT06836414 2026-04-13
Lung Cancer Screening CT for Firefighters
University of California, San Francisco
Phase NA Withdrawn
NCT06708702 2026-04-09
CopaÃba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy
Instituto Nacional de Cancer, Brazil
Phase 2 Withdrawn
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT07030699 2026-04-07
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT06152523 2026-04-06
MONAMI
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
NCT07308223 2026-04-06
Development of a Cloud-Based PRO (Patient-Reported Outcome) Management Program for Home-Based Cancer Pain Care
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase NA Withdrawn
NCT07511972 2026-04-06
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
Phase 2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT02143804 2026-04-02
exBOND
CG Oncology, Inc.
Phase 2 Withdrawn
NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT07049432 2026-04-01
CARMEN-803
University of Utah
Phase 1 Withdrawn
NCT05188573 2026-03-27
EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
ClearNote Health
Phase NA Withdrawn
NCT05982522 2026-03-27
IN10018 Combination Therapy in Previously-treated Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Withdrawn
NCT06222437 2026-03-23
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Methodist Health System
Phase 1 Withdrawn
NCT06282185 2026-03-23
Superman
Canisius-Wilhelmina Hospital
Phase NA Withdrawn
NCT06713798 2026-03-23
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn